Berliner Boersenzeitung - The scientist rewriting DNA, and the future of medicine

EUR -
AED 4.237331
AFN 76.151007
ALL 93.462127
AMD 420.754593
AOA 1059.187888
ARS 1712.70607
AUD 1.638048
AWG 2.076839
AZN 1.962396
BAM 1.956054
BBD 2.316901
BDT 142.048431
BHD 0.433756
BIF 3413.642921
BMD 1.1538
BND 1.476392
BOB 13.659772
BRL 5.855074
BSD 1.150349
BTN 109.664229
BWP 15.685035
BYN 3.346334
BYR 22614.474231
BZD 2.3136
CAD 1.616906
CDF 2624.894149
CHF 0.931307
CLF 0.026984
CLP 1065.475772
CNY 7.789653
CNH 7.787
COP 3617.485141
CRC 522.46779
CUC 1.1538
CUP 30.575692
CVE 110.279309
CZK 24.220334
DJF 204.846579
DKK 7.474632
DOP 66.738659
DZD 153.321894
EGP 58.830173
ERN 17.306996
ETB 183.826151
FJD 2.554455
FKP 0.855967
GBP 0.855479
GEL 3.017216
GGP 0.855967
GHS 13.447745
GIP 0.855967
GMD 84.833943
GNF 10098.310257
GTQ 8.777139
GYD 240.631222
HKD 9.048616
HNL 30.822999
HRK 7.531078
HTG 150.409516
HUF 363.809187
IDR 20806.470092
ILS 3.534031
IMP 0.855967
INR 110.075319
IQD 1506.995533
IRR 1586618.820668
ISK 141.998487
JEP 0.855967
JMD 182.113629
JOD 0.81806
JPY 182.006711
KES 148.954515
KGS 100.899857
KHR 4654.603935
KMF 492.672509
KRW 1653.429631
KWD 0.356686
KYD 0.958624
KZT 545.090726
LAK 26051.38017
LBP 103016.666425
LKR 386.170106
LRD 207.636941
LSL 19.027169
LTL 3.40687
LVL 0.697922
LYD 7.359955
MAD 10.746094
MDL 20.102608
MGA 4919.638324
MKD 61.532984
MMK 2422.467912
MNT 4147.377299
MOP 9.293106
MRU 46.231999
MUR 54.240444
MVR 17.83779
MWK 1994.658807
MXN 19.96891
MYR 4.709756
MZN 73.739442
NAD 19.027169
NGN 1569.755768
NIO 42.335493
NOK 10.943387
NPR 175.462766
NZD 1.956308
OMR 0.443698
PAB 1.150349
PEN 3.898506
PGK 5.150668
PHP 70.681927
PKR 319.477252
PLN 4.306453
PYG 6858.889942
QAR 4.205146
RON 5.247022
RSD 117.405233
RUB 91.498787
RWF 1688.719112
SAR 4.320894
SBD 9.323976
SCR 15.585022
SDG 692.279722
SEK 10.968711
SGD 1.478104
SLE 28.499921
SOS 657.385296
SRD 43.592286
STD 23881.324395
STN 24.503179
SVC 10.065306
SZL 19.024468
THB 38.467738
TJS 10.617578
TMT 4.049837
TND 3.381739
TRY 54.853367
TTD 7.811013
TWD 37.277308
TZS 3047.804584
UAH 51.343062
UGX 4319.560463
USD 1.1538
UYU 46.286006
UZS 13769.786631
VES 860.384288
VND 30345.509158
VUV 136.944309
WST 3.155055
XAF 656.042122
XAG 0.019811
XAU 0.000283
XCD 3.118201
XCG 2.073169
XDR 0.815906
XOF 656.042122
XPF 119.331742
YER 274.952077
ZAR 18.997987
ZMK 10385.586247
ZMW 21.608804
ZWL 371.523034
  • CMSC

    0.0300

    21.84

    +0.14%

  • BCC

    1.0000

    76.38

    +1.31%

  • NGG

    -0.4200

    79.97

    -0.53%

  • JRI

    0.0900

    12.96

    +0.69%

  • BTI

    -1.0400

    60.65

    -1.71%

  • CMSD

    0.0900

    22.11

    +0.41%

  • BCE

    -0.0200

    21.68

    -0.09%

  • RIO

    -0.3300

    96.85

    -0.34%

  • GSK

    -0.3800

    51.69

    -0.74%

  • VOD

    -0.3600

    15.78

    -2.28%

  • RYCEF

    -0.3100

    19.55

    -1.59%

  • RELX

    -1.1900

    35.42

    -3.36%

  • BP

    1.0000

    45.22

    +2.21%

  • AZN

    -1.7000

    169.64

    -1%

  • RBGPF

    0.0000

    69.21

    0%

The scientist rewriting DNA, and the future of medicine
The scientist rewriting DNA, and the future of medicine / Photo: Casey ATKINS - Broad Institute of Harvard and MIT,/AFP

The scientist rewriting DNA, and the future of medicine

A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose pioneering work is rewriting the building blocks of life with unprecedented precision.

Text size:

A professor at the Broad Institute of MIT and Harvard, Liu was awarded a Breakthrough Prize in Life Sciences on Saturday for developing two transformative technologies: one already improving the lives of patients with severe genetic diseases, the other poised to reshape medicine in the years ahead.

He spoke with AFP ahead of the Los Angeles ceremony for the prestigious Silicon Valley-founded award.

He will receive $3 million for his work on "base editing" and "prime editing," and plans to donate most of it to support his charitable foundation.

"The ability to change a DNA sequence of our choosing into a new sequence of our choosing is a fundamentally very powerful capability," the 51-year-old said, foreseeing uses not just in human medicine but areas like developing more nutritious or disease-resistant crops.

- Correcting the code -

DNA is made up of four chemical "letters" -- the nucleotide bases A, G, T and C. Mutations in this sequence cause thousands of human diseases, yet until recently, gene editing could only fix a limited number of them.

Even CRISPR-Cas9, the groundbreaking technology that earned a Nobel Prize in 2020, has major limitations.

It cuts both strands of the DNA helix, making it most useful to disrupt rather than correct genes, while the process can introduce new errors.

"Being able to use genome editing to treat genetic diseases requires, in most cases, ways to correct a DNA misspelling, not simply to disrupt a gene," Liu said.

That insight led his lab to develop base editing, which uses the Cas9 protein -- disabled so it can no longer cut both DNA strands -- to find a target DNA sequence and another enzyme to convert one letter to another -- for example, C to T or G to A.

Reversing the change -- from T to C or A to G -- was tougher. Liu's team overcame the challenge by engineering entirely new enzymes.

These base editors can now correct about 30 percent of the mutations that cause genetic diseases. The technology is already in at least 14 clinical trials.

In one of them, Beam Therapeutics -- which Liu co-founded -- announced it had treated patients of AATD, a rare genetic disorder affecting the lungs and liver, with a single drug infusion.

While traditional gene therapies often disrupt faulty genes or work around them, base editing repairs the mutation itself.

"This was the first time that humans have corrected a mutation that causes a genetic disease in a patient," Liu said.

- Cystic fibrosis hope -

Base editing, quickly dubbed "CRISPR 2.0," can't fix every mutation.

About 70 percent of the roughly 100,000 known disease-causing mutations remain out of its reach, including those caused by missing or extra letters.

To expand the toolkit, Liu's lab introduced prime editing in 2019 -- a method capable of replacing entire sections of faulty DNA with corrected sequences.

If CRISPR is like scissors that cut DNA, and base editors are like using a pencil to correct individual letters, then prime editing is the equivalent of a word processor's "find and replace" function.

Creating this tool required a series of breakthroughs Liu's team describes as "small miracles." The result is, he said, "the most versatile way we know of to edit the human genome."

Among the targets Liu and his team have already pursued with prime editing: cystic fibrosis, a common genetic disease usually caused by three missing DNA letters that causes thick mucus buildup in the lungs and digestive system.

Liu's lab has made much of its work freely accessible, sharing DNA blueprints through a nonprofit library used by tens of thousands of labs worldwide.

"The science we create -- which is ultimately funded by society, through governments and donors -- ultimately goes back to benefit society."

This year's Breakthrough Prize awards come at a fraught moment for US science, as President Donald Trump's government strips funding for institutions like the National Institutes of Health (NIH).

"The NIH is a treasure, not just for this country but for the world," said Liu. "Trying to dismantle the heart of what supports science in this country is like burning your seed corn."

(K.Müller--BBZ)